LAROPIPRANT - oversættelse til Dansk

• laropiprant

Eksempler på brug af Laropiprant på Engelsk og deres oversættelser til Dansk

Laropiprant is highly bound(>
Laropiprant er i høj grad(>

In Tredaptive tablets, laropiprant is in one of the layers, and the other layer contains nicotinic acid.
I Tredaptive- tabletter er der laropiprant i et af lagene, mens det andet lag indeholder nikotinsyre.

Pregnancy Tredaptive There are no data from the combined use of nicotinic acid and laropiprant in pregnant women.
Tredaptive Der foreligger ingen data for kombineret anvendelse af nicotinsyre og laropiprant til gravide.

Posology The starting dose is one modified-release tablet(1000 mg nicotinic acid/ 20 mg laropiprant) once a day.
Startdosis er én tablet med modificeret udløsning(1. 000 mg nicotinsyre/ 20 mg laropiprant) én gang dagligt.

fourth studies looked at the effectiveness of laropiprant in reducing the flushing caused by nicotinic acid.
fjerde undersøgelse så nærmere på laropiprants virkning med hensyn til at reducere flushing fremkaldt af nikotinsyre.

Laropiprant also has affinity for the thromboxane A2 receptor(TP)
Laropiprant har også affinitet til tromboxane A2- receptoren(TP)

The mean absolute bioavailability of laropiprant is approximately 71% following a 40 mg dose when administered as two modified-release tablets of nicotinic acid/ laropiprant after an overnight fast.
Efter en 40 mg dosis, når denne administreres som to tabletter med modificeret udløsning af nicotinsyre/ laropiprant efter en nats faste.

to nicotinic acid, laropiprant or any of the other ingredients.
over for nikotinsyre, laropiprant eller andre af indholdsstofferne.

Based on these data, laropiprant is not expected to cause interactions with substrates of CYP isozymes 3A4,
På basis af disse data forventes laropiprant ikke at medføre interaktion med substrater af CYP- isozymerne 3A4, 2C9, 2C8

Co-administration of laropiprant 40 mg with midazolam increased the AUC0-∞ and Cmax of 1'-hydroxymidazolam, a midazolam metabolite, by 98% and 59%, respectively.
Samtidig administration af laropiprant 40 mg og midazolam øgede AUC0- ∞ og Cmax for 1'- hydroxymidazolam, en midazolammetabolit, med henholdsvis 98% og 59.

following a 40 mg dose of laropiprant administered as two modified-release tablets of nicotinic acid/ laropiprant with food was approximately 17 hours.
efter en dosis på 40 mg laropiprant, som blev administreret som to tabletter med modificeret udløsning af nicotinsyre/ laropiprant sammen med mad, var ca.

the sedative effect of midazolam may be increased and caution should be used when laropiprant is co-administered with midazolam.
kan midazolams sedative virkning øges, og forsigtighed bør udvises, når laropiprant gives samtidigt med midazolam.

Laropiprant was not teratogenic in rats
Laropiprant var ikke teratogent hos rotter

a lipid modifying medicine, and• laropiprant, which reduces symptoms of flushing,
medicin som ændrer indholdet af fedtstoffer i blodet og• laropiprant, som mindsker rødmen,

which at therapeutic doses is a lipid-modifying agent, and laropiprant, a potent, selective antagonist of the prostaglandin D2(PGD2)
som i terapeutiske doser er et lipidmodificerende stof, og laropiprant, der er en potent, selektiv prostaglandin D2- antagonist(PGD2)

Laropiprant During controlled clinical trials in healthy subjects, single doses of up to 900 mg laropiprant and multiple doses up to 450 mg once daily for 10 days were generally well tolerated.
Laropiprant I kontrollerede kliniske undersøgelser med raske forsøgspersoner var enkeltdoser af op til 900 mg laropiprant og multiple doser op til 450 mg én gang dagligt i 10 dage generelt veltålt.

Laropiprant is not a substrate of human P-gp,
Laropiprant er ikke et substrat af humant P- gp,

In a clinical study, there was no meaningful effect of laropiprant on the inhibition of ADP-induced platelet aggregation by clopidogrel,
I en klinisk undersøgelse sås ingen relevant indvirkning af laropiprant på clopidogrels hæmning af ADP- induceret blodpladeaggregation,

In vitro studies have shown that the acyl glucuronide conjugate of laropiprant had at least a 65-fold reduced affinity for DP1 as compared to laropiprant;
In vitro- undersøgelser har vist, at laropiprants acylglucuronidkonjugat havde mindst 65 gange reduceret affinitet til DP1 i sammenligning med laropiprant; dette forventes derfor ikke

Laropiprant was not carcinogenic in 2 year studies in mice
Laropiprant var ikke karcinogent i 2- års undersøgelser på mus